ECSP22085835A - Moléculas de fijación para el tratamiento de cáncer - Google Patents

Moléculas de fijación para el tratamiento de cáncer

Info

Publication number
ECSP22085835A
ECSP22085835A ECSENADI202285835A ECDI202285835A ECSP22085835A EC SP22085835 A ECSP22085835 A EC SP22085835A EC SENADI202285835 A ECSENADI202285835 A EC SENADI202285835A EC DI202285835 A ECDI202285835 A EC DI202285835A EC SP22085835 A ECSP22085835 A EC SP22085835A
Authority
EC
Ecuador
Prior art keywords
cancer
treatment
binding molecules
fap
prevention
Prior art date
Application number
ECSENADI202285835A
Other languages
English (en)
Inventor
Inigo Tirapu
Joseph Ronald Tumang
Justin M Scheer
Abdallah Souabni
Pankaj Gupta
Daniel Christopher Rowe
Eric Borges
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP22085835A publication Critical patent/ECSP22085835A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a moléculas de fijación que se fijan específicamente a CD137 y FAP y su uso medicinal, composiciones farmacéuticas que las contienen y métodos para usarlas como agentes para el tratamiento y/o la prevención de cáncer.
ECSENADI202285835A 2020-05-19 2022-11-09 Moléculas de fijación para el tratamiento de cáncer ECSP22085835A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063026883P 2020-05-19 2020-05-19
US202063037241P 2020-06-10 2020-06-10
PCT/US2021/032990 WO2021236658A1 (en) 2020-05-19 2021-05-18 Binding molecules for the treatment of cancer

Publications (1)

Publication Number Publication Date
ECSP22085835A true ECSP22085835A (es) 2022-12-30

Family

ID=76502807

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202285835A ECSP22085835A (es) 2020-05-19 2022-11-09 Moléculas de fijación para el tratamiento de cáncer

Country Status (17)

Country Link
US (2) US12146000B2 (es)
EP (1) EP4153316A1 (es)
JP (2) JP2023504675A (es)
KR (1) KR20230012559A (es)
CN (1) CN116249555A (es)
AU (1) AU2021276332A1 (es)
BR (1) BR112022021447A2 (es)
CA (1) CA3180665A1 (es)
CL (1) CL2022003213A1 (es)
CO (1) CO2022016754A2 (es)
CR (1) CR20220586A (es)
EC (1) ECSP22085835A (es)
IL (1) IL298287A (es)
MX (1) MX2022014538A (es)
PE (1) PE20230784A1 (es)
PH (1) PH12022553153A1 (es)
WO (1) WO2021236658A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4153316A1 (en) 2020-05-19 2023-03-29 Boehringer Ingelheim International GmbH Binding molecules for the treatment of cancer
EP4164747A4 (en) * 2020-06-10 2024-07-10 Crystal Bioscience Inc. ANTI-BDNF ANTIBODIES AND METHODS OF USE THEREOF
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2026052000A1 (zh) * 2024-09-04 2026-03-12 上海迈晋生物医药科技有限公司 包含fap/4-1bb/cd40结合分子的药物组合物及其用途
CN119080935A (zh) * 2024-10-11 2024-12-06 上海市同仁医院 一种抗人SMIM45-107aa单克隆抗体及其用途

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3301833A1 (de) 1983-01-20 1984-07-26 Gesellschaft für Biotechnologische Forschung mbH (GBF), 3300 Braunschweig Verfahren zur simultanen synthese mehrerer oligonocleotide an fester phase
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1993005804A1 (en) 1991-09-18 1993-04-01 Sloan-Kettering Institute For Cancer Research Activated stromal fibroblast-specific antibody, f19 and methods of using the same
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1498427B1 (en) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
HUP9904697A3 (en) 1996-10-11 2001-06-28 Bristol Myers Squibb Company P Methods and compositions for immunomodulation
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
JP2002505574A (ja) 1997-04-30 2002-02-19 エンゾン，インコーポレイテッド ポリアルキレンオキシド修飾された単鎖ポリペプチド
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
EP1268550A2 (en) 2000-03-17 2003-01-02 Boehringer Ingelheim Pharma KG Human fap-alpha-specific antibodies
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
CA2433877C (en) 2001-01-17 2014-11-18 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
PE20021080A1 (es) 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
WO2004041862A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
KR20150139636A (ko) 2005-10-12 2015-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
RU2509085C2 (ru) 2008-01-28 2014-03-10 Медиммун Лимитед Стабилизированные антитела против ангиопоэтина-2 и их применение
EP2242773B1 (en) 2008-02-11 2017-06-14 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
US10265357B2 (en) 2008-10-08 2019-04-23 Viratherapeutics Gmbh Compositions, methods and uses for treating solid tumors using LCMV-GP-VSV pseudotype vectors
DE102008050860A1 (de) 2008-10-08 2010-04-15 Dorothee Von Laer LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
AU2010282508B2 (en) 2009-08-13 2015-05-28 Crystal Bioscience Inc. Transgenic animal for production of antibodies having minimal CDRs
JP2013506664A (ja) 2009-10-02 2013-02-28 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ リミテッド 抗線維芽細胞活性化タンパク質抗体並びにその方法及び使用
CN102753195A (zh) 2009-12-07 2012-10-24 小利兰·斯坦福大学托管委员会 用于增强抗肿瘤抗体疗法的方法
CN103221428B (zh) 2010-09-09 2016-02-10 辉瑞公司 4-1bb结合分子
EP2643349B1 (en) 2010-11-26 2019-09-04 Molecular Partners AG Designed repeat proteins binding to serum albumin
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
EP2764455B1 (en) 2011-10-05 2022-04-20 Opteon Corporation System and method for monitoring and/or controlling dynamic environments
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
EP3686219A1 (en) 2014-02-04 2020-07-29 Pfizer Inc Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
US9494125B2 (en) 2014-06-13 2016-11-15 Innova Electronics, Inc. System and method of ignition coil testing
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
EP3240908A2 (en) 2014-12-30 2017-11-08 F. Hoffmann-La Roche AG Methods and compositions for prognosis and treatment of cancers
US20170369592A1 (en) 2015-01-09 2017-12-28 Mabimmune Diagostics AG Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof
TW201632559A (zh) 2015-02-22 2016-09-16 索倫多醫療公司 結合ｃｄ１３７之抗體治療劑
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
US11008396B2 (en) 2015-05-21 2021-05-18 Alligator Bioscience Ab Polypeptides
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
MA43017A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
AU2016334623A1 (en) 2015-10-07 2018-02-15 F. Hoffmann-La Roche Ag Bispecific antibodies with tetravalency for a costimulatory TNF receptor
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
JP6384461B2 (ja) 2015-12-03 2018-09-05 株式会社デンソー リリーフ弁装置、及び、それを用いる高圧ポンプ
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
DE102016000353A1 (de) 2016-01-14 2017-07-20 Liebherr-Components Biberach Gmbh Kran-, Baumaschinen- oder Flurförderzeug-Simulator
JP6783312B2 (ja) 2016-01-25 2020-11-11 ファイザー・インク がんを処置するためのｏｘ４０アゴニストおよび４−１ｂｂアゴニストモノクローナル抗体の組み合わせ
RU2018139339A (ru) 2016-04-22 2020-05-22 Эллигейтор Биосайенс Аб Новые биспецифические полипептиды против cd137
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
SG11201810591VA (en) 2016-05-27 2018-12-28 Abbvie Biotherapeutics Inc Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US10360201B2 (en) 2016-07-11 2019-07-23 Investcloud Inc Data exchange common interface configuration
WO2018055060A1 (en) 2016-09-21 2018-03-29 Amal Therapeutics Sa Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer
US11673971B2 (en) 2016-09-23 2023-06-13 Marengo Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
JP6997778B2 (ja) 2016-11-10 2022-02-10 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 距離に基づく腫瘍分類
GB201619648D0 (en) 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
EP3360898A1 (en) * 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
EP3565843A1 (en) 2017-01-03 2019-11-13 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
WO2018127787A1 (en) 2017-01-06 2018-07-12 Eutilex Co., Ltd. Anti-human 4-1 bb antibodies and use thereof
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
WO2018134787A2 (en) 2017-01-20 2018-07-26 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd137+ cells
US10123435B2 (en) 2017-02-02 2018-11-06 Lg Electronics Inc. Display control module and display device including the same
PT3443010T (pt) 2017-02-17 2024-10-21 Ose Immunotherapeutics Novos anticorpos anti-sirpa e suas aplicações terapêuticas
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
BR112020000719A2 (pt) 2017-07-11 2020-07-14 Compass Therapeutics Llc anticorpos agonistas que ligam o cd137 humano e seus usos
CN111448210B (zh) 2017-07-26 2024-05-14 四十七公司 抗SIRP-α抗体及相关方法
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
EP3470428A1 (en) 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting cd137 and methods of use thereof
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
PE20200849A1 (es) 2017-10-10 2020-08-20 Numab Therapeutics AG Anticuerpo multiespecifico
CN111183159B (zh) 2017-10-10 2024-09-03 努玛治疗有限公司 靶向cd137的抗体及其使用方法
MY205342A (en) 2017-11-01 2024-10-16 Hoffmann La Roche Bispecific 2+1 contorsbodies
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
US20210015866A1 (en) 2018-03-23 2021-01-21 La Jolla Institute For Allergy And Immunology Tissue resident memory cell profiles, and uses thereof
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
PE20211491A1 (es) 2018-09-27 2021-08-11 Celgene Corp PROTEINAS DE FIJACION A SIRPa Y METODOS DE USO DE ESTAS
TWI894135B (zh) 2019-01-25 2025-08-21 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
EP4153316A1 (en) 2020-05-19 2023-03-29 Boehringer Ingelheim International GmbH Binding molecules for the treatment of cancer

Also Published As

Publication number Publication date
PH12022553153A1 (en) 2024-02-26
US20210363273A1 (en) 2021-11-25
CN116249555A (zh) 2023-06-09
JP2023504675A (ja) 2023-02-06
AU2021276332A1 (en) 2022-11-17
US20250136720A1 (en) 2025-05-01
WO2021236658A1 (en) 2021-11-25
CA3180665A1 (en) 2021-11-25
IL298287A (en) 2023-01-01
BR112022021447A2 (pt) 2022-12-13
MX2022014538A (es) 2022-12-15
CL2022003213A1 (es) 2023-06-30
KR20230012559A (ko) 2023-01-26
CR20220586A (es) 2023-01-09
JP2024054284A (ja) 2024-04-16
EP4153316A1 (en) 2023-03-29
TW202214303A (zh) 2022-04-16
CO2022016754A2 (es) 2022-11-29
US12146000B2 (en) 2024-11-19
PE20230784A1 (es) 2023-05-11

Similar Documents

Publication Publication Date Title
CO2022016754A2 (es) Moléculas de fijación para el tratamiento de cáncer
CL2024003895A1 (es) Proteínas que se unen a nkg2d, flt3 y cd16; composición farmacéutica; y su uso.
CL2021001171A1 (es) Compuestos de anillo fusionado.
BR112023021068A2 (pt) Compostos, composições e métodos para tratar câncer
CO2021003036A2 (es) Compuestos de anillo fusionado
BR112022021884A2 (pt) Proteínas que se ligam a nkg2d, cd16 e clec12a
CY1121120T1 (el) Αρυλ- ή ετεροαρυλ-υποκατεστημενες ενωσεις βενζολιου
DOP2022000229A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
BR112022002442A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
CO2022016899A2 (es) Moduladores de il-17a
ECSP22083174A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
MX383164B (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
CO2022018636A2 (es) Moduladores de il-17a
BR112022027101A2 (pt) Anticorpos multiespecíficos que se ligam a bcma
CL2021001739A1 (es) Inhibidores de la proteína de activación de fibroblastos.
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
MX2021004566A (es) Compuestos terapeuticos.
MX2022013396A (es) Compuestos de tetrahidroisoquinolina como activadores de nrf2.
MX2024008450A (es) Piperidinil-metil-purina aminas enriquecidas con deuterio y compuestos relacionados y su uso en el tratamiento de enfermedades y condiciones
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
MX2022013398A (es) Compuestos de tetrahidroisoquinolina como activadores de nrf2.
CL2021001944A1 (es) Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias